Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids
Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids
复制标题
DOI：
10.1126/science.1077215
复制
发表时间：
2003-02-07
期刊：
影响因子：
56.9
通讯作者：
Rübsamen-Waigmann, H
中科院分区：
文献类型：
--
作者：
Deres, K;Schröder, CH;Rübsamen-Waigmann, H
慢性乙型肝炎病毒（HBV）感染是肝脏疾病的主要原因。只有干扰素- α和病毒聚合酶的核苷类抑制剂3TC和阿德福韦被批准用于治疗。然而，这些疗法受到干扰素副作用和病毒对核苷类抑制剂的大量耐药性的限制。迫切需要适用于单一疗法或联合疗法的强效新型抗病毒化合物。我们描述了具有体外和体内抗病毒活性的HBV核衣壳成熟的非核苷类抑制剂。这些抑制剂在未来的治疗方案中有潜力对抗慢性HBV感染。
Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-alpha and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.